CliffBio
biologic

Riabni

rituximab-arrx

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameRiabni
Active ingredientrituximab-arrx
Strength100MG/10ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2020
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Riabni patent cliff — loss of exclusivity — | CliffBio